ASSESSMENT OF ENDOGENOUS AND CAR T-CELL IMMUNITY FOLLOWING ANTI-PD-1 AGENT AS A TRANSITION STEP TO PHASE 2 COMBINATION IMMUNOTHERAPY
$609,922FY2019Department of the ArmyDOD
Sloan-Kettering Institute For Cancer Research
Sloan-Kettering Institute For Cancer Research